文献速递淋巴瘤

基于慢性淋巴细胞白血病微环境激活的基因表达检测预测疾病进展

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression.
PubMed 文献 · Blood Adv · 2022-01-01

研究在NanoString平台分析200个微环境信号相关基因,训练队列(n=154)中CLL15检测(15基因特征)与至首次治疗时间相关(HR 2.83,95%CI 2.17-3.68,P<.001),外部验证队列(n=112)确认其预后价值(HR 1.71,95%CI 1.15-2.52,P=.007),且CLL15评分在多变量分析中与IPS-E CLL独立相关。

要点

  • CLL15检测基于15个微环境信号相关基因表达特征,在训练队列中与至首次治疗时间相关(HR 2.83)。
  • CLL15评分在外部独立验证队列中预后价值得到确认(HR 1.71,95%CI 1.15-2.52,P=.007)。
  • CLL15评分在预后能力上优于IGHV突变状态和IPS-E CLL,多变量分析中与IPS-E CLL独立相关。

核心结论

  • 新开发并验证的CLL15检测成功将微环境信号等既往基因特征转化为具有预后意义的基因表达检测。

研究设计与样本

  • 研究描述了基于NanoString平台分析200个微环境信号相关基因的基因表达特征的训练和验证,用于预测CLL患者早期进展。
  • 训练队列样本量为154例,外部独立验证队列样本量为112例。

主要发现

  • 训练队列(n=154)中CLL15检测(含15基因特征)与至首次治疗时间相关(HR 2.83,95%CI 2.17-3.68,P<.001)。
  • 外部独立验证队列(n=112)中CLL15评分的预后价值得到确认(HR 1.71,95%CI 1.15-2.52,P=.007)。
  • CLL15评分在预后能力上优于IGHV突变状态和无症状早期CLL国际预后评分(IPS-E)。
  • 多变量分析中CLL15评分(HR 1.83,95%CI 1.32-2.56,P<.001)和IPS-E CLL(HR 2.23,95%CI 1.59-3.12,P<.001)与至首次治疗时间独立相关。

关键数值与推荐

  • CLL15检测包含15个基因特征,基于200个微环境信号相关基因在NanoString平台分析。
  • 训练队列中CLL15检测与至首次治疗时间关联的HR为2.83(95%CI 2.17-3.68,P<.001)。
  • 验证队列中CLL15评分的HR为1.71(95%CI 1.15-2.52,P=.007)。
  • 多变量分析中CLL15评分的HR为1.83(95%CI 1.32-2.56,P<.001),IPS-E CLL的HR为2.23(95%CI 1.59-3.12,P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several gene expression profiles with a strong correlation with patient outcomes have been previously described in chronic lymphocytic leukemia (CLL), although their applicability as biomarkers in clinical practice has been particularly limited. Here we describe the training and validation of a gene expression signature for predicting early progression in patients with CLL based on the analysis of 200 genes related to microenvironment signaling on the NanoString platform. In the training cohort (n = 154), the CLL15 assay containing a 15-gene signature was associated with the time to first treatment (TtFT) (hazard ratio [HR], 2.83; 95% CI, 2.17-3.68; P < .001). The prognostic value of the CLL15 score (HR, 1.71; 95% CI, 1.15-2.52; P = .007) was further confirmed in an external independent validation cohort (n = 112). Notably, the CLL15 score improved the prognostic capacity over IGHV mutational status and the International Prognostic Score for asymptomatic early-stage (IPS-E) CLL. In multivariate analysis, the CLL15 score (HR, 1.83; 95% CI, 1.32-2.56; P < .001) and the IPS-E CLL (HR, 2.23; 95% CI, 1.59-3.12; P < .001) were independently associated with TtFT. The newly developed and validated CLL15 assay successfully translated previous gene signatures such as the microenvironment signaling into a new gene expression-based assay with prognostic implications in CLL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Abrisqueta P, Medina D, Villacampa G, et al. A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Adv. 2022. PMID: 35973197. doi:10.1182/bloodadvances.2022007508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。